EP1993510A1 - Médicament contenant de la fluoroquinolone - Google Patents

Médicament contenant de la fluoroquinolone

Info

Publication number
EP1993510A1
EP1993510A1 EP07846476A EP07846476A EP1993510A1 EP 1993510 A1 EP1993510 A1 EP 1993510A1 EP 07846476 A EP07846476 A EP 07846476A EP 07846476 A EP07846476 A EP 07846476A EP 1993510 A1 EP1993510 A1 EP 1993510A1
Authority
EP
European Patent Office
Prior art keywords
chloride
alkyl
optionally
dimethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07846476A
Other languages
German (de)
English (en)
Inventor
Iris Heep
Kristine Fraatz
Hans-Jürgen HAMANN
Markus Edingloh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38171208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1993510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health GmbH filed Critical Bayer Animal Health GmbH
Priority to DK11151745.4T priority Critical patent/DK2340809T3/en
Priority to PL11151745T priority patent/PL2340809T3/pl
Priority to EP11151745.4A priority patent/EP2340809B1/fr
Publication of EP1993510A1 publication Critical patent/EP1993510A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Definitions

  • the invention relates to the use of quaternary ammonium compounds for the prevention of precipitation of fluoroquinolones from their solutions and stable, compatible drugs, in particular suitable parenteral administration containing in dissolved form a fluoroquinolone and a quaternary ammonium compound.
  • DE-OS 3 831 514 describes solutions with quinolones by the use of metal ions, in particular by calcium ions. Improved solubility of quinolones is also disclosed in JP 02-264724 and by M. Nakano, M. Yamamoto, T. Arita in Chem. Pharm. Bull., Interactions of Aluminum, Magnesium and Calcium ions with
  • EP-A 287 926 a detailed purification process is described specifically for the synthesis of fluoroquinolones, so that it does not result in the production of (injection) solutions to particle formation.
  • Fluoroquinolone feedstocks with a particularly low level of contamination by metal ions must be used to ensure that the solutions remain free of particles.
  • a likewise frequently chosen way out of the problem of particle formation is, for example, the freeze-drying of solutions.
  • surfactants are not well tolerated when administered parenterally. This is due among other things to the affinity of the surface-active substances to components of the cell walls. Surface-active substances with a particularly pronounced affinity to cell walls are therefore u.a. also used as a disinfectant or as a preservative. This also applies to preservatives from the group of quaternary ammonium compounds, such as. B. benzalkonium chloride.
  • a ready - to - use solution as an injection solution also known as a "ready to use formulation” is therefore advantageous
  • the fluoroquinolone in the appropriate amount passes into the serum. Again, this is not a matter of course with injectable formulations of fluoroquinolones and may also depend on the particular animal species.
  • Formulations are provided with fluoroquinolones which contain a sufficient concentration of the fluoroquinolone, which are well tolerated locally after parenteral administration in various animal species that are stable under pharmaceutical storage conditions, as well as free of particle formation, and have a favorable serum kinetic profile.
  • the invention relates to:
  • the invention further relates to:
  • a medicament containing in dissolved form is a medicament containing in dissolved form:
  • Fluoroquinolones are compounds disclosed, inter alia, in the following documents: US 4,670,444 (Bayer AG), US 4,472,405 (Riker Labs), US 4,730,000 (Abbott), US 4,861
  • Moxifloxacin Norfloxacin, Ofloxacin, Orbifloxacin, Pefloxacin, Temafloxacin, Tosufloxacin, Sarafloxacin, Sparfloxacin.
  • a preferred group of fluoroquinolones are those of the formula (I) or (II):
  • X is hydrogen, halogen, C M alkyl, Ci -4 -alkoxy, NH 2,
  • R 4 represents optionally substituted by hydroxy or methoxy straight-chain or branched C 1 -C 4 -alkyl, cyclopropyl, acyl having 1 to 3 C-atoms,
  • R 5 is hydrogen, methyl, phenyl, thienyl or pyridyl
  • R 6 is hydrogen or C M -alkyl
  • R 7 is hydrogen or C 1-4 -alkyl
  • R 8 is hydrogen or C 1-4 -alkyl
  • R 1 is an alkyl radical having 1 to 3 carbon atoms, cyclopropyl, 2-fluoroethyl, methoxy, 4-
  • R 2 is hydrogen or optionally methoxy or 2-methoxyethoxy-substituted alkyl having 1 to 6 carbon atoms and cyclohexyl, benzyl, 2-oxopropyl, phenacyl, ethoxycarbonylmethyl, pivaloyloxymethyl,
  • R 3 is hydrogen, methyl or ethyl
  • R 1 is optionally halogen-substituted C 1 -C 3 -alkyl or cyclopropyl
  • R 2 is hydrogen or C 1 -C 4 -alkyl
  • R 4 is optionally hydroxyl-substituted straight-chain or branched C 1 -C 3 -alkyl, oxalkyl having 1 to 4 C atoms,
  • R 5 is hydrogen, methyl or phenyl
  • R 6 is hydrogen or methyl
  • R 7 is hydrogen or methyl
  • R 8 is hydrogen or methyl
  • R! represents cyclopropyl
  • R 2 is hydrogen, methyl or ethyl
  • R 4 is methyl, optionally substituted by hydroxy ethyl
  • R 5 is hydrogen or methyl
  • R 6 is hydrogen
  • R 7 is hydrogen or methyl
  • R 8 is hydrogen
  • Marbofloxacin may be mentioned as a preferred example of a fluoroquinolone of the formula (ET):
  • fluoroquinolones which may be mentioned are the compounds described in WO 97/31001, in particular 8-cyano-1-cyclopropyl-7 - ((1S, 6S) -2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-l, 4-dihydro-4-oxo-3-quinolinecarboxylic acid (pradofloxacin) having the formula
  • the fluoroquinolones may be in the form of their racemates or in enantiomeric forms. Both the pure enantiomers and mixtures thereof can be used according to the invention.
  • Suitable salts are pharmaceutically usable acid addition salts and basic salts.
  • salts of hydrochloric acid for example, the salts of hydrochloric acid,
  • Suitable pharmaceutically usable basic salts are the alkali metal salts, for example the sodium or potassium salts, the alkaline earth metal salts, for example the magnesium or calcium salts; the zinc salts, the silver salts and the guanidinium salts.
  • Hydrates are understood as meaning both the hydrates of the fluoroquinolones themselves and the hydrates of their salts.
  • An example is pradofloxacin, which forms a stable trihydrate (see WO 2005/097789).
  • Fluoroquinolones may possibly form different crystal modifications as a solid.
  • Advantageous for the pharmaceutical compositions of the present invention are those modifications which have corresponding solubility properties.
  • the fluoroquinolone for animals with a body weight up to about 80 kg typically in a proportion of 0.1 to 15%, preferably 0.5 to 15% and more preferably used with 1 to 15%.
  • the fluoroquinolone is typically used in a proportion of from 1 to 30%, preferably 3 to 25% and particularly preferably 4 to 20%. Unless otherwise stated, here and below the percentages are percent (M / V). This means: mass of the substance in grams per 100 ml of finished solution.
  • the medicaments of the invention may contain further suitable active ingredients, such as e.g. Analgesics, in particular NSAIDs (nonsteroidal, antiinflammatory substances).
  • NSAIDs nonsteroidal, antiinflammatory substances
  • Such NSAIDs can e.g. Meloxicam, flunixin, ketoprofen, carprofen, metamizole or (acetyl) salicylic acid.
  • Quaternary ammonium compounds in the context of this invention are usually organic
  • Ammonium compounds having non-polar substituents and various counterions such as chloride, bromide, iodide or fluoride may have. These are preferably compounds of the general formula (II):
  • R 1 to R 4 are identical or different and are Ci.js-alkyl, which may optionally be interrupted by one or more times oxygen and substituted with hydroxyl or with an optionally substituted with one or more halogen atoms or Ci-s-alkyl radicals substituted aryl radical can be, or
  • R 1 to R 4 by ring closure of three residues 5- or 6-membered heterocyclic radicals, such as. B.
  • At least one of the radicals R 1 to R 4 preferably has a chain length of 8 to 18, particularly preferably 12 to 16 carbon atoms.
  • Aryl is preferably a phenyl radical which is optionally substituted by 1 or 2 radicals selected from halogen, in particular chlorine, and C 1-8 -alkyl.
  • halogen in particular chlorine
  • C 1-8 -alkyl examples are alkyl-dimethyl-benzylammoniumchloride, particularly benzalkonium chloride [(C 8 i.
  • alkyl-dimethyl-benzyl-ammonium chloride or N- (C 12 -C 8) -alkyl-benzyldimethylammoniurn- chloride having average molecular weights ranging from about 380 , Benzethonium chloride (diisobutylphenoxyethoxyethyl-dimethylbenzyl-ammonium chloride), dichlorobenzyl-dimethyl-alkylammonium chloride, benzoxonium chloride (benzyl-dodecyl-bis (2-hydroxyethyl) -ammonium chloride), cetrimonium bromide (N-hexadecyl-N, N trimethylammonium bromide, di- (C 8 -C 8 ) -alkyldimethylammonium chloride, for example dioctyldimethylammonium chloride or di-n-decyldimethylammonium chloride, cetylpyridin
  • the quaternary ammonium compounds are usually used in concentrations of 0.001 to 10%, preferably from 0.005 to 6% and particularly preferably from 0.005 to 3%.
  • the percentages mean% (M / V).
  • the medicaments according to the invention may contain, in addition to the quaternary ammonium compounds, further substances which may avoid particle formation; e.g. poloxamers
  • Lecithins polyvinylpyrrolidones, cosolvents, antioxidants or complexing agents. These are also usually used in concentrations of 0.001 to 20%, preferably from 0.01 to 10% and particularly preferably from 0.05 to 3%. The percentages mean% (M / V).
  • the liquid formulations may contain substances which improve the local tolerance when applied. Examples which may be mentioned are radical scavengers or antioxidants, e.g.
  • Vitamin E water-soluble vitamin E esters or vitamin C, butylated hydroxyanisole, butylhydroxytoluene, cysteamine, cysteine, glutathione, thioglycol, thiolactic acid, sodium disulfide or acetylcysteine.
  • cyclodextrins eg, hydroxyproypl-cyclodextrin
  • sodium EDTA ethylenediaminetetraacetic acid
  • polyvinlypyrrolidone dexpanthenol
  • salts of fatty acids such as sodium caprylate
  • salts of polyvalent metal cations eg Me 2+, Me 3+
  • the alkaline earth metals and here in particular the magnesium in its salt forms amino acids and including especially arginine or lysine, poloxamers, poloxamines, cosolvents such as n-butanol, glycerol, polyethylene glycol, propylene glycol or dimethylacetamide, dextrans, creatine, creatinine, acids such as gluconolactonic acid , Lactic acid, embonic acid, citric acid, tartaric acid, mucic acid or hyaluronic acid, containing lecithins
  • the salts of polyvalent metal cations are preferably used, preferably the alkaline earth metal salts, in particular magnesium salts.
  • Substances which improve the compatibility are usually used in concentrations of 0.05 to 10%, preferably 0.1 to 8% and particularly preferably 0.5 to 5%. The percentages mean% (M / V).
  • the liquid formulation may contain water or water-miscible substances.
  • examples which may be mentioned are glycerol, propylene glycol, polyethylene glycols, compatible alcohols such as ethanol, benzyl alcohol or n-butanol, ethyl lactate, ethyl acetate, triacetin, N-methylpyrrolidone, propylene carbonate, glycofurol, dimethylacetamide, 2-pyrrolidone, isopropylidene glycerol, or glycerol formal.
  • Combinations of the solvents are also conceivable. Preference is given to water-based formulations in which, of course, further solvents and co-solvents may be present.
  • the liquid formulation can also contain oils in the form of an emulsion in addition to water or water-miscible substances.
  • oils include the vegetable, animal and synthetic oils such as cottonseed oil, sesame oil, soybean oil, medium-chain triglycerides of a chain length of Cj 2 -C 18 , propylene glycol octanoate decanoate or paraffin called.
  • the solvency is usually contained in concentrations of up to 98.5%, preferably up to 97%, particularly preferably up to 96.5%.
  • concentrations of solvency are more than 50%, preferably more than 60%, particularly preferably more than 70%.
  • the percentages mean% (M / V).
  • the formulations according to the invention may also contain co-solvents, preferably when the formulations contain water; the cosolvents can improve the solubility of certain formulation ingredients.
  • the cosolvents are usually used in proportions of 1 to 10%, preferably from 3 to 8% (percentages in each case M / V).
  • cosolvents examples which may be mentioned as cosolvents are: pharmaceutically acceptable alcohols, dimethyl sulfoxide, ethyl lactate, ethyl acetate, triacetin, N-methylpyrrolidone, propylene carbonate, propylene glycol, glycofurol, dimethylacetamide, 2-pyrrolidone, isopropylideneglycerol, glycerol formal, glycerol and polyethylene glycols.
  • Kosolvenz are particularly suitable pharmaceutically acceptable alcohols, such as.
  • ethanol benzyl alcohol or n-butanol. Mixtures of the abovementioned solvents can also be used as cosolvents.
  • Preservatives may be included in the liquid formulation.
  • the abovementioned quaternary ammonium compounds generally have a preserving effect, eg. Benzalkonium chloride, benzethonium chloride or cetylpyridinium chloride.
  • Other useful preservatives include: Aliphatic alcohols such as benzyl alcohol, ethanol, n-butanol, phenol, cresols, chlorobutanol, para-hydroxybenzoic acid esters (in particular the methyl and propyl esters), salts or the free acids of the carboxylic acids, such as sorbic acid, benzoic acid, lactic acid or propionic acid.
  • compositions according to the invention may comprise further customary, pharmaceutically acceptable additives and auxiliaries.
  • auxiliaries As examples may be mentioned
  • antioxidants such as sulfites (Na sulfite, Na-metabisulfite), organic sulfides (cystine, cysteine, cysteamine, methionine, thioglycerol, thioglycolic acid, thiolactic acid) phenols (tocopherols, as well as vitamin E and vitamin E TPGS (d- alpha-tocopherylpolyethylene glycol 1000 succinate), butylhydroxyanisole, butylhydroxytoluene, octyl and dodecyl gallate), organic acids (ascorbic acid, citric acid, tartaric acid, lactic acid) and their salts and esters
  • Wetting agents such as, for example, fatty acid salts, fatty alkyl sulfates, fatty alkyl sulfonates, linear alkylbenzenesulfonates, fatty alkyl polyethylene glycol ether sulfates, fatty alkyl polyethylene glycol ethers, alkylphenol polyethylene glycol ethers, alkyl polyglycosides, fatty acid N-methylglucamides, polysorbates, sorbitan fatty acid esters and poloxamers.
  • fatty acid salts such as, for example, fatty acid salts, fatty alkyl sulfates, fatty alkyl sulfonates, linear alkylbenzenesulfonates, fatty alkyl polyethylene glycol ether sulfates, fatty alkyl polyethylene glycol ethers, alkylphenol polyethylene glycol ethers, alkyl polyglycosides, fatty acid N-methylglucamides, polysorbates,
  • substances for isotonization e.g. Sodium chloride, glucose or glycerin.
  • the pH of the liquid formulations is 2-11, preferably 3-8 and more preferably 4-7.6.
  • compositions according to the invention can be prepared by reacting the fluoroquinolone in the
  • Solvens is dispersed, the substances to improve the compatibility and, where appropriate, to avoid particle formation also be supplemented. Kosolventien and other ingredients such. Preservatives may already be added to the solvent or added later.
  • Particle formation can also first be solved in the solvent and subsequently the fluoroquinolone can be added.
  • the pharmaceutical preparations according to the invention are generally suitable for use in humans and animals. They are preferably used in animal husbandry and animal breeding in livestock, breeding, zoo, laboratory, experimental and hobby animals.
  • the productive and breeding animals include mammals such as cattle, horses, sheep, pigs, goats, camels, water buffalo, donkeys, rabbits, fallow deer, reindeer, fur animals such as mink, chinchilla, raccoon and birds such as quails, chickens, geese, Turkeys, ducks, pigeons and bird species for home and zoo keeping.
  • Laboratory and experimental animals include mice, rats, guinea pigs, golden hamsters,
  • the hobby animals include rabbits, hamsters, rats, guinea pigs, mice, horses, reptiles, corresponding birds, dogs and cats.
  • fish are called, namely useful, breeding, aquarium and ornamental fish of all ages, living in fresh and salt water.
  • the preparations according to the invention are preferably used in hobby animals such as horses, rabbits, cats and dogs. In particular, they are suitable for use in cats and dogs.
  • Examples of preferred farm animals are cattle, sheep, pork, goat, turkey and chicken. Particularly preferred farm animals are beef and pork.
  • the application can be both prophylactic, metaphylactic and therapeutic.
  • liquid formulations according to the invention are preferably added as solutions or emulsions, particularly preferred are homogeneous solutions.
  • formulations described herein can be delivered in various ways to the target organism (human or animal).
  • they can be parenteral, especially by
  • Injection eg subcutaneously, intramuscularly, intravenously, intramammary, intraperitoneally
  • dermally orally, rectally, vaginally or nasally
  • parenteral administration is preferred, in particular by injection.
  • the use with the substances mentioned leads to medicaments with good solubility of the active ingredient and good stability of the formulation, in particular with regard to precipitations. Furthermore, the medicament according to the invention is distinguished by good compatibility and suitable serum kinetics in the various animal species mentioned, in particular after parenteral administration. Examples
  • the formulations of the following examples are prepared by mixing or dissolving the indicated starting materials in Aqua per injections.
  • the pH of the solutions can be adjusted by adding acids or bases.
  • the solutions for injection are sterile filtered and transferred into suitable containers.
  • Pradofloxacin can be used as anhydrate or as
  • Trihydrate are used; the numerical values are calculated respectively for the anhydrate.
  • enrofloxacin 0.5 g of enrofloxacin, 1.5 g of magnesium chloride hexahydrate and 0.01 g of benzalkonium chloride are dissolved in 50 ml of water per injection and, if appropriate, the pH is adjusted to 6.0 with potassium hydroxide.
  • pradofloxacin calculated as pure pradofloxacin, used as trihydrate
  • magnesium chloride hexahydrate 1.5 g
  • benzalkonium chloride 1.5 g
  • pradofloxacin 0.75 g of pradofloxacin, 1.5 g of magnesium chloride hexahydrate and 0.005 g of benzethonium chloride are dissolved in 50 ml of water per injection and, if appropriate, the pH is adjusted to 6.0 with sodium hydroxide.
  • pradofloxacin calculated as pure pradofloxacin, used as trihydrate
  • Magnesium chloride hexahydrate and 0.01 g of benzalkonium chloride are dissolved in 50 ml of water per injection and, if appropriate, the pH is adjusted to 6.0 with sodium hydroxide.
  • the formulation also has an influence on the serum pharmacokinetic (PK) profile.
  • PK serum pharmacokinetic
  • Different formulations show significant differences in the serum concentration-time curve. For quinolones, fast absorption, high peak concentration, and long elimination phase curves are preferred.
  • the table below shows the PK profile of a formulation according to the invention. The test system used has been described in the "Local Compatibility" section.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation de composés d'ammonium quaternaire destinés à empêcher des précipitations de fluoroquinolones de leurs solutions. L'invention concerne également des médicaments stables, compatibles, particulièrement appropriés pour l'application parentérale, et qui renferment, sous forme dissoute, une fluoroquinolone et un composé d'ammonium quaternaire.
EP07846476A 2006-03-08 2007-02-23 Médicament contenant de la fluoroquinolone Withdrawn EP1993510A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK11151745.4T DK2340809T3 (en) 2006-03-08 2007-02-23 Medicament containing fluoroquinolones
PL11151745T PL2340809T3 (pl) 2006-03-08 2007-02-23 Lek zawierający fluorochinoliny
EP11151745.4A EP2340809B1 (fr) 2006-03-08 2007-02-23 Formulations de médicaments contenant des fluoroquinolones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006010643A DE102006010643A1 (de) 2006-03-08 2006-03-08 Arzneimittel enthaltend Fluorchinolone
PCT/EP2007/001569 WO2008025380A1 (fr) 2006-03-08 2007-02-23 Médicament contenant de la fluoroquinolone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP11151745.4A Division EP2340809B1 (fr) 2006-03-08 2007-02-23 Formulations de médicaments contenant des fluoroquinolones

Publications (1)

Publication Number Publication Date
EP1993510A1 true EP1993510A1 (fr) 2008-11-26

Family

ID=38171208

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11151745.4A Active EP2340809B1 (fr) 2006-03-08 2007-02-23 Formulations de médicaments contenant des fluoroquinolones
EP07846476A Withdrawn EP1993510A1 (fr) 2006-03-08 2007-02-23 Médicament contenant de la fluoroquinolone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11151745.4A Active EP2340809B1 (fr) 2006-03-08 2007-02-23 Formulations de médicaments contenant des fluoroquinolones

Country Status (31)

Country Link
US (1) US10231925B2 (fr)
EP (2) EP2340809B1 (fr)
JP (1) JP5584418B2 (fr)
KR (2) KR20150046367A (fr)
CN (2) CN101394836B (fr)
AR (1) AR059696A1 (fr)
AU (1) AU2007291622B2 (fr)
BR (1) BRPI0708613B1 (fr)
CA (1) CA2645037C (fr)
CR (1) CR10270A (fr)
DE (1) DE102006010643A1 (fr)
DK (1) DK2340809T3 (fr)
EC (1) ECSP088716A (fr)
ES (1) ES2542206T3 (fr)
GT (1) GT200800173A (fr)
HU (1) HUE025044T2 (fr)
IL (1) IL193429A0 (fr)
MX (1) MX2008011344A (fr)
MY (1) MY152885A (fr)
NZ (1) NZ571046A (fr)
PE (1) PE20071021A1 (fr)
PL (1) PL2340809T3 (fr)
PT (1) PT2340809E (fr)
RU (1) RU2527327C2 (fr)
SI (1) SI2340809T1 (fr)
SV (1) SV2008003014A (fr)
TW (1) TWI494105B (fr)
UA (1) UA96753C2 (fr)
UY (1) UY30191A1 (fr)
WO (1) WO2008025380A1 (fr)
ZA (1) ZA200807484B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405890A1 (fr) 2001-05-15 2004-04-07 OOO "Corning" Matiere thermochromique

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
WO2010069493A1 (fr) * 2008-12-18 2010-06-24 Bayer Animal Health Gmbh Combinaison améliorée de principes actifs contenant un antibiotique et un médicament anti-inflammatoire non stéroïdien (nsaid)
EP2332916A3 (fr) 2009-11-19 2011-08-03 Krka Tovarna Zdravil, D.D., Novo Mesto Procede de la preparation du marbofloxacin et produits intermediares
CN101716141B (zh) * 2010-01-20 2011-11-30 白求恩医科大学制药厂 一种氟罗沙星注射液及其制备方法
GB2480276A (en) * 2010-05-11 2011-11-16 Michael Hilary Burke Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation
RU2682171C2 (ru) * 2016-10-11 2019-03-15 Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") Фармацевтическая комбинированная композиция для лечения гнойных ран на основе фторхинолонов (варианты)
BR112019009132A2 (pt) * 2016-11-07 2019-07-16 Jubilant Life Sciences Ltd composições antimicrobianas sinergísticas
JP7257322B2 (ja) * 2017-02-13 2023-04-13 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング プラドフロキサシンを含有する液体組成物
WO2019023842A1 (fr) 2017-07-31 2019-02-07 Dow Silicones Corporation Compositions durcissant à l'humidité
JP2020529490A (ja) 2017-07-31 2020-10-08 ダウ シリコーンズ コーポレーション 湿分硬化性組成物
CN111620901B (zh) * 2020-06-08 2023-03-21 蚌埠医学院第二附属医院 一种含硅氧烷基的氟喹诺酮化合物、其制备方法及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002130A2 (fr) 1997-07-11 1999-01-21 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions ophtalmiques stables au stockage contenant du diclofenac et de l'ofloxacine
WO2000064429A1 (fr) 1999-04-22 2000-11-02 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Composition pharmaceutique agissant sur des etats pathologiques induits par bacteries, virus, champignons, levures et protozoaires
WO2004082658A1 (fr) 2003-03-20 2004-09-30 Bayer Healthcare Ag Systeme de liberation controlee contenant de l'acetate isobutyrate de saccharose

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (fr) 1985-09-18 1990-05-05 Pfizer
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US5225413A (en) * 1988-09-16 1993-07-06 Bayer-Aktiengesellschaft pH-neutral aqueous solutions of quinolone-carboxylic acids
DE3831514A1 (de) 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
JP2832535B2 (ja) 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
WO1991009616A1 (fr) 1989-12-22 1991-07-11 Yale University Antibiotiques a la quinolone encapsules dans des vesicules de lipides
JP3153549B2 (ja) 1989-12-29 2001-04-09 アボツト・ラボラトリーズ キノロンカルボン酸―金属イオン―酸錯体
FR2665635A1 (fr) 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
DE69224071T2 (de) * 1991-09-17 1998-05-07 Alcon Lab Inc Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen
EP0868183B1 (fr) * 1995-12-21 2002-01-30 Pfizer Inc. Formulations de quinolone injectables
JP4338217B2 (ja) * 1996-02-23 2009-10-07 バイエル・アニマル・ヘルス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 置換可能な８―シアノ―１―シクロプロピル―７―（２，８―ジアザビシクロ―［４．３．０］―ノナン―８―イル）―６―フルオロ―１，４―ジヒドロ―４―オキソ―３―キノリンカルボン酸およびそれらの誘導体
WO1998018492A1 (fr) 1996-10-25 1998-05-07 Yoshitomi Pharmaceutical Industries Ltd. Procede pour empecher la precipitation de medicaments
GB9714218D0 (en) * 1997-07-04 1997-09-10 Allied Therapeutics Ltd Peritoneal dialysis fluid
HUP0100051A3 (en) * 1997-09-15 2002-08-28 Procter & Gamble Antimicrobial quinolones, their compositions and uses
US6387928B1 (en) * 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
DE19937115A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
TR200200737T2 (tr) * 1999-09-24 2002-08-21 Alcon, Inc. Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
CA2516429A1 (fr) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Composition ophtalmique stable
RU2248199C1 (ru) * 2003-06-02 2005-03-20 Открытое Акционерное Общество "Акционерное Курганское общество медицинских препаратов и изделий "Синтез" (ОАО "Синтез") Глазные капли и способ их получения
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
DE102004015981A1 (de) 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
PL1776109T3 (pl) * 2004-08-13 2009-06-30 Schering Plough Ltd Farmaceutyczna formulacja zawierająca antybiotyk, triazol i kortykosteroid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002130A2 (fr) 1997-07-11 1999-01-21 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions ophtalmiques stables au stockage contenant du diclofenac et de l'ofloxacine
WO2000064429A1 (fr) 1999-04-22 2000-11-02 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Composition pharmaceutique agissant sur des etats pathologiques induits par bacteries, virus, champignons, levures et protozoaires
WO2004082658A1 (fr) 2003-03-20 2004-09-30 Bayer Healthcare Ag Systeme de liberation controlee contenant de l'acetate isobutyrate de saccharose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008025380A1
VEILLET F. ET AL: "Dictionnaire Medicaments Veterinaires et des produits de Sante Animale, 11e edition", 2001, pages: 807 - 808, XP003028184

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405890A1 (fr) 2001-05-15 2004-04-07 OOO "Corning" Matiere thermochromique

Also Published As

Publication number Publication date
JP2009529015A (ja) 2009-08-13
CN104208064A (zh) 2014-12-17
EP2340809A2 (fr) 2011-07-06
IL193429A0 (en) 2009-05-04
RU2008139635A (ru) 2010-04-20
DK2340809T3 (en) 2015-07-20
CN101394836A (zh) 2009-03-25
HUE025044T2 (en) 2016-01-28
WO2008025380A1 (fr) 2008-03-06
PT2340809E (pt) 2015-08-28
PE20071021A1 (es) 2007-11-25
CR10270A (es) 2009-03-18
MX2008011344A (es) 2008-11-12
AU2007291622B2 (en) 2013-08-01
NZ571046A (en) 2012-05-25
ECSP088716A (es) 2008-11-27
US10231925B2 (en) 2019-03-19
SV2008003014A (es) 2010-05-17
CN101394836B (zh) 2017-08-29
BRPI0708613A2 (pt) 2011-06-07
EP2340809B1 (fr) 2015-04-15
CA2645037C (fr) 2016-06-28
TWI494105B (zh) 2015-08-01
DE102006010643A1 (de) 2007-09-13
JP5584418B2 (ja) 2014-09-03
CA2645037A1 (fr) 2008-03-06
SI2340809T1 (sl) 2015-08-31
TW200810756A (en) 2008-03-01
EP2340809A3 (fr) 2012-09-19
KR20080106253A (ko) 2008-12-04
ES2542206T3 (es) 2015-08-03
US20100009979A1 (en) 2010-01-14
MY152885A (en) 2014-11-28
UY30191A1 (es) 2007-10-31
RU2527327C2 (ru) 2014-08-27
AU2007291622A1 (en) 2008-03-06
ZA200807484B (en) 2009-11-25
BRPI0708613B1 (pt) 2021-10-19
PL2340809T3 (pl) 2015-09-30
GT200800173A (es) 2009-09-14
UA96753C2 (ru) 2011-12-12
AR059696A1 (es) 2008-04-23
KR20150046367A (ko) 2015-04-29

Similar Documents

Publication Publication Date Title
EP2340809B1 (fr) Formulations de médicaments contenant des fluoroquinolones
EP2121024B1 (fr) Stabilisation de vitamine b12
US8231903B2 (en) Controlled release system
EP1993549A1 (fr) Formulations de médicaments contenant des fluoroquinolones
DE10337191A1 (de) Neue Verwendung von Chinolon-Antibiotika
WO2010069493A1 (fr) Combinaison améliorée de principes actifs contenant un antibiotique et un médicament anti-inflammatoire non stéroïdien (nsaid)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090311

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150925

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160206